MAPK3 and neoplasm: In contrast, efficacy was limited in tumors such as KRAS-mutated NSCLC, likely because these tumor cells are not addicted to ERK1/2 signaling or can compensate for its inhibition via alternative pathways (NCT02972034) [120].